Worsening vasomotor symptoms in the setting of estradiol and semaglutide: a case report.

IF 3 3区 医学 Q1 OBSTETRICS & GYNECOLOGY
Anna E Parker
{"title":"Worsening vasomotor symptoms in the setting of estradiol and semaglutide: a case report.","authors":"Anna E Parker","doi":"10.1097/GME.0000000000002621","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To encourage continued research of the delayed gastric emptying effect of glucagon-like peptide-1 receptor agonists and its effect on absorption of orally administered estrogen.</p><p><strong>Methods: </strong>A case is reported of a 51-year-old postmenopausal female prescribed oral estrogen for the treatment of vasomotor symptoms of menopause. The patient reported mood changes and worsening of vasomotor symptoms during semaglutide dose titration. A search for current literature was conducted to investigate any possible connection between semaglutide and the patient's increased symptoms of menopause.</p><p><strong>Results: </strong>During the semaglutide dose titration, the patient experienced changes in mood as well as increased incidence and intensity of vasomotor symptoms. After review of current available literature, a hypothesis was made that glucagon-like peptide-1 receptor agonists may temporarily decrease absorption of oral estrogen. The patient's semaglutide dose titration was slowed with subsequent resolution of mood changes and vasomotor symptoms. The patient's symptom resolution aligns with available literature suggesting that the absorption of some medications is impaired when a glucagon-like peptide-1 receptor agonist is first initiated or dose-increased due to delayed gastric emptying, which subsequently resolves after prolonged stimulation of glucagon-like peptide-1 receptors.</p><p><strong>Conclusions: </strong>Continued research should be considered to identify if there is an effect of the absorption of oral estrogen after the initial dose and/or after a dose titration of semaglutide.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Menopause: The Journal of The North American Menopause Society","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/GME.0000000000002621","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To encourage continued research of the delayed gastric emptying effect of glucagon-like peptide-1 receptor agonists and its effect on absorption of orally administered estrogen.

Methods: A case is reported of a 51-year-old postmenopausal female prescribed oral estrogen for the treatment of vasomotor symptoms of menopause. The patient reported mood changes and worsening of vasomotor symptoms during semaglutide dose titration. A search for current literature was conducted to investigate any possible connection between semaglutide and the patient's increased symptoms of menopause.

Results: During the semaglutide dose titration, the patient experienced changes in mood as well as increased incidence and intensity of vasomotor symptoms. After review of current available literature, a hypothesis was made that glucagon-like peptide-1 receptor agonists may temporarily decrease absorption of oral estrogen. The patient's semaglutide dose titration was slowed with subsequent resolution of mood changes and vasomotor symptoms. The patient's symptom resolution aligns with available literature suggesting that the absorption of some medications is impaired when a glucagon-like peptide-1 receptor agonist is first initiated or dose-increased due to delayed gastric emptying, which subsequently resolves after prolonged stimulation of glucagon-like peptide-1 receptors.

Conclusions: Continued research should be considered to identify if there is an effect of the absorption of oral estrogen after the initial dose and/or after a dose titration of semaglutide.

在雌二醇和西马鲁肽设置恶化血管舒缩症状:一个病例报告。
目的:鼓励继续研究胰高血糖素样肽-1受体激动剂的胃延迟排空作用及其对口服雌激素吸收的影响。方法:报告1例51岁绝经后女性口服雌激素治疗绝经期血管舒缩症状。患者报告在西马鲁肽剂量滴定期间情绪变化和血管舒缩症状恶化。对当前文献进行了检索,以调查西马鲁肽与患者更年期症状增加之间的任何可能联系。结果:在西马鲁肽剂量滴定期间,患者情绪发生变化,血管舒缩症状的发生率和强度增加。在回顾了现有文献后,我们提出了一种假设,即胰高血糖素样肽-1受体激动剂可能会暂时减少口服雌激素的吸收。随着患者情绪变化和血管舒缩症状的消退,患者的西马鲁肽剂量滴定减慢。患者的症状缓解与现有文献一致,表明当胰高血糖素样肽-1受体激动剂首次使用或由于胃排空延迟而剂量增加时,某些药物的吸收受损,随后在胰高血糖素样肽-1受体的长时间刺激后消退。结论:应考虑继续研究,以确定在西马鲁肽初始剂量和/或剂量滴定后口服雌激素的吸收是否有影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.40
自引率
7.40%
发文量
330
审稿时长
3-8 weeks
期刊介绍: ​Menopause, published monthly, provides a forum for new research, applied basic science, and clinical guidelines on all aspects of menopause. The scope and usefulness of the journal extend beyond gynecology, encompassing many varied biomedical areas, including internal medicine, family practice, medical subspecialties such as cardiology and geriatrics, epidemiology, pathology, sociology, psychology, anthropology, and pharmacology. This forum is essential to help integrate these areas, highlight needs for future research, and enhance health care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信